Amgen stock holds near 52-week high as Repatha data and Q2 2026 beat support rally

Amgen stock is trading close to its 52-week high after a Q2 2026 earnings beat and new Repatha cardiovascular data, with the shares showing strong momentum on the Nasdaq.

Amgen (ISIN US0311621009) stock is trading near its 52-week high after a Q2 2026 earnings beat and fresh cardiovascular data for its cholesterol drug Repatha helped extend a strong rally that has lifted the shares about 31% year to date as of late August 2026, according to market commentary compiled on September 1, 2026.

Repatha data adds to Q2 2026 earnings strength

The latest catalyst for Amgen came from new clinical data for Repatha, its PCSK9 inhibitor for lowering LDL cholesterol, presented at the European Society of Cardiology Congress 2026. According to an analysis on Simply Wall St, Amgen reported Phase 3 VESALIUS-CV trial results showing Repatha reduced the risk of death for high-risk adults without prior heart attack or stroke, giving investors a new survival-data angle on a product that is already well established in the market.

The clinical update has arrived on top of solid financial momentum. As summarized by previous coverage on ad-hoc-news.de, Amgen delivered a Q2 2026 earnings beat and raised parts of its guidance, underpinning the share price strength in recent weeks. In that context, Amgen reached a new 52-week high of 447.03 USD in late August 2026, with the company’s market capitalization around 233 billion USD, according to a recent article discussing Amgen’s rally.

Stock near 52-week high on Nasdaq listing

On its primary Nasdaq listing, Amgen stock closed at 432.42 USD on August 28, 2026, at 4:00 p.m. Eastern Time, according to an earlier ad-hoc-news.de analysis of the shares. That closing level left the stock only about 3.3% below its 52-week high of 447.03 USD and clearly above both the 50-day moving average of 388.64 USD and the 200-day moving average of 364.71 USD as of that date, signaling a strong technical uptrend supported by recent fundamental strength.

A separate comparison overview on Pluang cites Amgen trading at around 432 USD and notes a market capitalization of about 232.41 billion USD, placing the biotech among the larger components of the S and P 500 index. For investors, the proximity of the current price to the 52-week high and the distance above key moving averages underline that the market is already pricing in a robust outlook, making future data and earnings reports crucial to sustain the rally.

Regulatory headwind in the United Kingdom

Alongside the positive flow of clinical and financial news, Amgen faces a regulatory headwind in one of its European markets. According to a report on Global Banking and Finance, the United Kingdom’s Medicines and Healthcare products Regulatory Agency has suspended the use of Amgen’s autoimmune drug Tavneos for new patients due to concerns over unreliable data in the supporting evidence, as summarized on September 1, 2026. The decision affects prescriptions for new patients in the UK, creating a potential drag on Tavneos growth in that market and reminding investors that regulatory scrutiny remains a key risk factor for large biopharmaceutical companies.

For the broader DACH investor base, the UK action is relevant because European regulatory decisions can influence sentiment toward large US biopharma names traded via secondary listings or over-the-counter instruments in Germany, Switzerland and Austria. While Amgen is not a constituent of the DAX or MDAX, German investors can access the stock through its Nasdaq listing and various certificates, and will typically factor UK regulatory developments into their risk assessment, particularly if such decisions extend to wider European Union or Swiss reviews.

Representative product: Repatha and cardiovascular focus

A key product underpinning Amgen’s current story is Repatha, its PCSK9 inhibitor for lowering LDL cholesterol and reducing cardiovascular risk. The drug has long been part of Amgen’s portfolio, but the latest VESALIUS-CV survival data presented at the European Society of Cardiology Congress 2026 suggest that Repatha may have a stronger role in primary prevention for high-risk adults without a prior heart attack or stroke, according to the Simply Wall St analysis mentioned above. This new angle could expand the addressable market and lengthen the product’s growth trajectory, a factor that helps explain why recent clinical updates have been closely watched by the market.

Amgen stock valuation and investor perspective

With Amgen stock closing at 432.42 USD on August 28, 2026, only about 3.3% below the 52-week high of 447.03 USD and well above its 50-day and 200-day moving averages, the shares reflect a strong combination of recent earnings momentum and positive clinical data, while also pricing in expectations for continued cash flow generation and pipeline progress. The market capitalization near 232 billion USD places Amgen among the larger healthcare names in the S and P 500, suggesting that any future changes in guidance, major regulatory decisions or additional trial results for key assets like Repatha will have a visible impact not only on the company itself but also on sector indices and healthcare-focused portfolios.

Amgen stock at a glance

• Company: Amgen Inc.
• ISIN: US0311621009
• Ticker: AMGN
• Trading venue: Nasdaq
• Price (as of August 28, 2026, 16:00): 432.42 USD
• Market capitalization: 232.41 billion USD (as of August 28, 2026)
• Sector / Industry: Health Care / Biotechnology
• Index membership: S and P 500